BARD1 Life Sciences inks critical deal to develop autoantibody test
Published 21-MAY-2018 11:38 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
BARD1 Life Sciences (ASX:BD1) has penned an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test using ProcartaPlex® technology.
BD1 is a small-cap biotech company focused on developing and commercialising non-invasive cancer diagnostics. Its proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.
This agreement defines the development of a multiplex immunoassay in kit format for the semi-quantitative detection of autoantibodies against 20 BARD1 peptides using ProcartaPlex® technology for performance on Luminex® instrumentation for BD1’s research and evaluation.
The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using the ProcartaPlex® technology for BD1’s research use.
The first application of the ProcartaPlex® technology is to the BARD1-Ovarian test, which BD1 plans to develop for detection of ovarian cancer.
The custom research assay development project began on May 18 and is expected to take around nine months, with deliverables including Assay Feasibility Report, Development Report, Protocol, Standard Operating Procedures, Assay Validation Report, BARD1-autoantibody kits for research and evaluation, and transfer documentation.
If the development project is successful, the two companies will discuss potential for Thermo Fisher to supply research autoantibody kits to BD1 for its use in research studies.
BD1 CEO, Dr Leearne Hinch, said: “We are pleased to work with such an experienced partner. The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019.”
As always, it should be noted that BD1 is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
